PDF(Pubmed)
Abstract：
UNASSIGNED: Chronic kidney disease (CKD) is significantly influenced by mitochondrial dysfunction (MD). Previous research suggests that methylmalonic acid (MMA) is involved in MD. Consequently, we aimed to investigate associations between blood MMA level and the prevalence of CKD as well as mortality in patients with CKD.
UNASSIGNED: The study included 23,587 individuals from National Health and Nutrition Examination Survey (NHANES). The NHANES datasets from 1999-2004 and 2011-2014 were utilized as separate primary and validation subsets. There were 3,554 patients with CKD. The association of blood MMA level with the prevalence of CKD was investigated using weighted logistic regression. Meanwhile, we employed weighted Cox regression models to evaluate the association between blood MMA level and all-cause mortality in patients with CKD.
UNASSIGNED: Blood MMA levels had a significant positive association with urinary albumin-to-creatinine ratio (β=45.29, P=0.01) and negative association with estimated glomerular filtration rate (β=-15.27, P<0.001) in CKD patients. Blood MMA level exhibited a significant increase in participants with CKD compared with those without CKD (7.60±0.86 vs. 7.03±0.62, P<0.001). The level of blood MMA was significantly associated with the prevalence of CKD [odds ratio (OR): 1.32, 95% confidence interval (CI): 1.05-1.64, P=0.01]. In addition, blood MMA level was significantly associated with all-cause mortality in CKD participants [hazard ratio (HR): 1.26, 95% CI: 1.11-1.43, P<0.001] after adjusting for other potential predictors.
UNASSIGNED: Increased blood MMA levels were associated with more severe kidney impairment and increased risk of both the prevalence of CKD and mortality in participants with CKD.
UNASSIGNED: The study included 23,587 individuals from National Health and Nutrition Examination Survey (NHANES). The NHANES datasets from 1999-2004 and 2011-2014 were utilized as separate primary and validation subsets. There were 3,554 patients with CKD. The association of blood MMA level with the prevalence of CKD was investigated using weighted logistic regression. Meanwhile, we employed weighted Cox regression models to evaluate the association between blood MMA level and all-cause mortality in patients with CKD.
UNASSIGNED: Blood MMA levels had a significant positive association with urinary albumin-to-creatinine ratio (β=45.29, P=0.01) and negative association with estimated glomerular filtration rate (β=-15.27, P<0.001) in CKD patients. Blood MMA level exhibited a significant increase in participants with CKD compared with those without CKD (7.60±0.86 vs. 7.03±0.62, P<0.001). The level of blood MMA was significantly associated with the prevalence of CKD [odds ratio (OR): 1.32, 95% confidence interval (CI): 1.05-1.64, P=0.01]. In addition, blood MMA level was significantly associated with all-cause mortality in CKD participants [hazard ratio (HR): 1.26, 95% CI: 1.11-1.43, P<0.001] after adjusting for other potential predictors.
UNASSIGNED: Increased blood MMA levels were associated with more severe kidney impairment and increased risk of both the prevalence of CKD and mortality in participants with CKD.
摘要：
■慢性肾脏疾病（CKD）受线粒体功能障碍（MD）的显着影响。先前的研究表明甲基丙二酸（MMA）与MD有关。因此,我们旨在调查血液MMA水平与CKD患病率以及CKD患者死亡率之间的关系.
■该研究包括来自国家健康和营养调查（NHANES）的23,587名个人。1999-2004年和2011-2014年的NHANES数据集被用作单独的主要和验证子集。CKD患者3,554例。采用加权logistic回归分析血MMA水平与CKD患病率的相关性。同时,我们采用加权Cox回归模型评估CKD患者血MMA水平与全因死亡率之间的相关性.
■CKD患者血MMA水平与尿白蛋白/肌酐比值呈显著正相关（β=45.29，P=0.01），与估计肾小球滤过率呈负相关（β=-15.27，P<0.001）。与没有CKD的参与者相比，患有CKD的参与者的血液MMA水平显着增加（7.60±0.86vs.7.03±0.62,P<0.001)。血MMA水平与CKD患病率显著相关[比值比(OR):1.32,95%置信区间(CI):1.05~1.64,P=0.01]。此外,校正其他潜在预测因子后,CKD参与者的血MMA水平与全因死亡率显著相关[风险比(HR):1.26,95%CI:1.11~1.43,P<0.001].
■血液MMA水平升高与更严重的肾损害和CKD患者的CKD患病率和死亡率风险增加相关。
■该研究包括来自国家健康和营养调查（NHANES）的23,587名个人。1999-2004年和2011-2014年的NHANES数据集被用作单独的主要和验证子集。CKD患者3,554例。采用加权logistic回归分析血MMA水平与CKD患病率的相关性。同时,我们采用加权Cox回归模型评估CKD患者血MMA水平与全因死亡率之间的相关性.
■CKD患者血MMA水平与尿白蛋白/肌酐比值呈显著正相关（β=45.29，P=0.01），与估计肾小球滤过率呈负相关（β=-15.27，P<0.001）。与没有CKD的参与者相比，患有CKD的参与者的血液MMA水平显着增加（7.60±0.86vs.7.03±0.62,P<0.001)。血MMA水平与CKD患病率显著相关[比值比(OR):1.32,95%置信区间(CI):1.05~1.64,P=0.01]。此外,校正其他潜在预测因子后,CKD参与者的血MMA水平与全因死亡率显著相关[风险比(HR):1.26,95%CI:1.11~1.43,P<0.001].
■血液MMA水平升高与更严重的肾损害和CKD患者的CKD患病率和死亡率风险增加相关。
